Ambulatory cardiac monitors’ clinical and economic outcomes vary; one long-term continuous monitor brand showed greater arrhythmia diagnosis, fewer retests and cardiovascular events, and lower health ...
Edwards Lifesciences (Irvine, CA) has announced that it has received FDA 510(k) approval for its ClearSight noninvasive monitor that, in conjunction with the company's EV1000 clinical platform, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results